Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 2
1904 1
1928 2
1939 1
1940 2
1943 1
1944 1
1945 2
1946 1
1947 4
1948 2
1949 6
1950 3
1951 8
1952 7
1953 5
1954 4
1955 10
1956 9
1957 12
1958 23
1959 13
1960 6
1961 6
1962 7
1963 12
1964 11
1965 23
1966 15
1967 17
1968 8
1969 12
1970 11
1971 12
1972 21
1973 28
1974 10
1975 17
1976 18
1977 25
1978 22
1979 18
1980 13
1981 15
1982 7
1983 14
1984 23
1985 19
1986 27
1987 20
1988 33
1989 32
1990 29
1991 39
1992 48
1993 36
1994 47
1995 56
1996 47
1997 49
1998 54
1999 64
2000 58
2001 82
2002 73
2003 109
2004 133
2005 180
2006 177
2007 192
2008 241
2009 249
2010 259
2011 330
2012 399
2013 389
2014 413
2015 487
2016 500
2017 495
2018 483
2019 506
2020 604
2021 652
2022 628
2023 267
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8,149 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. Among authors: banerjee s. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. J Am Acad Dermatol. 2023. PMID: 35820547 Free article. Clinical Trial.
CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging.
Cui H, Xie N, Banerjee S, Dey T, Liu RM, Antony VB, Sanders YY, Adams TS, Gomez JL, Thannickal VJ, Kaminski N, Liu G. Cui H, et al. Among authors: banerjee s. Am J Respir Crit Care Med. 2022 Aug 15;206(4):459-475. doi: 10.1164/rccm.202109-2151OC. Am J Respir Crit Care Med. 2022. PMID: 35687485
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: banerjee s. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.
Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D; International Pediatric Nephrology Association. Trautmann A, et al. Among authors: banerjee s. Pediatr Nephrol. 2023 Mar;38(3):877-919. doi: 10.1007/s00467-022-05739-3. Epub 2022 Oct 21. Pediatr Nephrol. 2023. PMID: 36269406 Free PMC article. Review.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. DiSilvestro P, et al. Among authors: banerjee s. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36082969 Free PMC article. Clinical Trial.
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: banerjee s. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Targeting NaPi2b in ovarian cancer.
Banerjee S, Drapkin R, Richardson DL, Birrer M. Banerjee S, et al. Cancer Treat Rev. 2023 Jan;112:102489. doi: 10.1016/j.ctrv.2022.102489. Epub 2022 Nov 14. Cancer Treat Rev. 2023. PMID: 36446254 Free article. Review.
Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, Shin MJ, Merino VF, Zheng L, Brayton C, Pomper MG, Banerjee SR. Boinapally S, et al. Among authors: banerjee sr. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4369-4381. doi: 10.1007/s00259-022-05933-3. Epub 2022 Aug 15. Eur J Nucl Med Mol Imaging. 2022. PMID: 35965291
8,149 results